Literature DB >> 19221856

Executive dysfunction in treated phenylketonuric patients.

Bahare Azadi1, Arshia Seddigh, Mehdi Tehrani-Doost, Javad Alaghband-Rad, Mahmoud Reza Ashrafi.   

Abstract

OBJECTIVES: Executive function deficits have been described in early and continuously treated patients with phenylketonuria (PKU). The aim of this study was to examine performance on executive function tasks of treated patients with PKU diagnosed by 2 years of age. PATIENTS AND METHODS: Ten patients with PKU and normal intelligence score who were diagnosed before the age of 2 years and subsequently treated continuously, were compared with 15 typically developing control children on a battery of neuropsychological tests, including the tower of London (TOL), continuous performance test (CPT), and Stroop test.
RESULTS: PKU cases showed significantly poorer performance on the TOL task compared to the control group with the difference being significant in the first three levels of the test. With the CPT, PKU cases had significantly more omission errors than control subjects. On the Stroop test there was no statistically significant difference between the groups. No significant correlation was found between the concurrent serum phenylalanine (Phe) level and results of the executive tests in PKU patients.
CONCLUSION: This study identified executive dysfunction in early-treated PKU patients with normal IQ, particularly in the planning and attention domains. Further studies are required to compare the results with those from other neurodevelopmental disorders such as ADHD and autism, to establish whether the pattern of findings is specific to PKU.

Entities:  

Mesh:

Year:  2009        PMID: 19221856     DOI: 10.1007/s00787-009-0738-8

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  24 in total

1.  Incidence of phenylketonuria in Iran estimated from consanguineous marriages.

Authors:  J Koochmeshgi; A Bagheri; S M Hosseini-Mazinani
Journal:  J Inherit Metab Dis       Date:  2002-02       Impact factor: 4.982

2.  Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

Authors:  P Griffiths; R Campbell; P Robinson
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

3.  Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics.

Authors:  Reinhold Feldmann; Jonas Denecke; Michael Pietsch; Michael Grenzebach; Josef Weglage
Journal:  Pediatr Res       Date:  2002-06       Impact factor: 3.756

4.  Kinetic constants for blood-brain barrier amino acid transport in conscious rats.

Authors:  L P Miller; W M Pardridge; L D Braun; W H Oldendorf
Journal:  J Neurochem       Date:  1985-11       Impact factor: 5.372

5.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

6.  Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria.

Authors:  M Luciana; J Sullivan; C A Nelson
Journal:  Child Dev       Date:  2001 Nov-Dec

7.  Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive function.

Authors:  Kathryn DeRoche; Marilyn Welsh
Journal:  Dev Neuropsychol       Date:  2008       Impact factor: 2.253

8.  Autism and phenylketonuria.

Authors:  Sabrina Baieli; Lorenzo Pavone; Concetta Meli; Agata Fiumara; Mary Coleman
Journal:  J Autism Dev Disord       Date:  2003-04

9.  Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria.

Authors:  G L Arnold; C J Vladutiu; C C Orlowski; E M Blakely; J DeLuca
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

10.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

View more
  10 in total

1.  Differential effects of low-phenylalanine protein sources on brain neurotransmitters and behavior in C57Bl/6-Pah(enu2) mice.

Authors:  Emily A Sawin; Sangita G Murali; Denise M Ney
Journal:  Mol Genet Metab       Date:  2014-02-08       Impact factor: 4.797

2.  Autism Spectrum Disorder and Phenylketonuria: Dyzygotic Twins with Double Syndrome.

Authors:  Esra Demirci
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

3.  Processing speed and executive abilities in children with phenylketonuria.

Authors:  Alicia L Janos; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Neuropsychology       Date:  2012-08-06       Impact factor: 3.295

4.  Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful.

Authors:  A M Das; K Goedecke; U Meyer; N Kanzelmeyer; S Koch; S Illsinger; T Lücke; H Hartmann; K Lange; H Lanfermann; L Hoy; X-Q Ding
Journal:  JIMD Rep       Date:  2013-11-13

5.  Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.

Authors:  Christopher J Fonnesbeck; Melissa L McPheeters; Shanthi Krishnaswami; Mary Louise Lindegren; Tyler Reimschisel
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

6.  Pre-attentive processing in children with early and continuously-treated PKU. Effects of concurrent Phe level and lifetime dietary control.

Authors:  Leo M J de Sonneville; Stephan C J Huijbregts; Robert Licht; Joseph A Sergeant; Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-05-04       Impact factor: 4.982

7.  Large Neutral Amino Acids (LNAAs) Supplementation Improves Neuropsychological Performances in Adult Patients with Phenylketonuria.

Authors:  Iris Scala; Maria Pia Riccio; Maria Marino; Carmela Bravaccio; Giancarlo Parenti; Pietro Strisciuglio
Journal:  Nutrients       Date:  2020-04-15       Impact factor: 5.717

8.  Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.

Authors:  Iris Scala; Daniela Concolino; Anna Nastasi; Giulia Esposito; Daniela Crisci; Simona Sestito; Stefania Ferraro; Lucia Albano; Margherita Ruoppolo; Giancarlo Parenti; Pietro Strisciuglio
Journal:  Nutrients       Date:  2021-11-10       Impact factor: 5.717

9.  Quality of Life and the Associated Psychological Factors in Caregivers of Children with PKU.

Authors:  Javad Mahmoudi-Gharaei; Saeedeh Mostafavi; Nargess Alirezaei
Journal:  Iran J Psychiatry       Date:  2011

10.  Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride.

Authors:  Teresa D Douglas; Usha Ramakrishnan; Julie A Kable; Rani H Singh
Journal:  Health Qual Life Outcomes       Date:  2013-12-30       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.